Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Denali Therapeutics Inc

Company price
18.42 USD 0.42 ( 2.33%)
Last update at 2026-11-18T20:59:00Z
VOLUME
1618098
Market Cap
3192.45M

Momentum Score

…

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
17.91
Low
18.58
High
52 Week Price Range
12.58
Low
23.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Denali Therapeutics is a clinical-stage biotech developing targeted therapies for neurodegenerative diseases using a proprietary blood–brain barrier transport platform to improve CNS delivery. Long-term growth drivers include clinical readouts, validation of the delivery platform and potential collaborations to support development. Investors may find it attractive because it appears positioned to address unmet needs in CNS disorders where brain delivery limits current treatments.
Principal risks are material clinical and regulatory uncertainty, development-stage financing needs and competition from larger companies pursuing alternative CNS approaches.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
18.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-418.78M
Debt / Equity
0.04
ROE
-45.69%
Net Debt
-163.04M
ROCE
-48.97%
Diluted EPS TTM
-2.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -512.44M -422.70M -145.19M -325.97M -291.16M
Net income -512.54M -422.77M -145.22M -325.99M -290.58M
Selling general administrative 97.10M 105.44M 103.35M 90.47M 79.06M
Selling and marketing expenses - - 16.73M - -
Gross profit -11.18M -7.79M 330.53M 108.46M 48.66M
Reconciled depreciation 14.81M 8.99M 18.64M 10.38M 8.59M
Ebit -512.44M -501.88M -196.70M -340.74M -304.34M
Ebitda -497.63M -492.89M -179.97M -330.36M -295.75M
Depreciation and amortization 14.81M 8.99M 16.73M 10.38M 8.59M
Non operating income net other - - - - 4.59M
Operating income -555.34M -487.34M -196.70M -340.74M -295.75M
Other operating expenses 555.34M 487.34M 527.23M 449.21M 344.41M
Interest expense - - - 14.77M 13.19M
Tax provision 0.10M 0.07M -0.01M 0.02M -0.57M
Interest income 42.90M 64.64M 51.51M 14.77M 4.59M
Net interest income 42.90M 64.64M 45.04M 14.77M 4.59M
Income tax expense 0.10M 0.07M 0.03M 0.02M -0.57M
Total revenue 0.00M 0.00M 330.53M 108.46M 48.66M
Total operating expenses 544.16M 487.34M 527.23M 449.21M 344.41M
Cost of revenue 11.18M 7.79M 16.73M - -
Total other income expense net 42.90M 64.64M 51.51M 14.77M 4.59M
Net income from continuing ops -512.54M -422.77M -124.43M -325.99M -290.58M
Net income applicable to common shares - - - -325.99M -290.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1144.85M 1374.18M 1153.92M 1460.24M 1404.16M
Other current assets 30.60M 29.93M 26.93M 36.10M 30.60M
Total liab 131.09M 144.50M 122.96M 417.81M 441.87M
Total stockholder equity 1013.76M 1229.68M 1030.95M 1042.43M 962.29M
Other current liab 85.47M 79.04M 61.24M 63.76M 47.71M
Common stock 1.89M 1.77M 1.71M 1.69M 1.55M
Capital stock 1.89M 1.77M 1.71M 1.69M 1.55M
Retained earnings -2051.52M -1538.98M -1116.21M -970.99M -645.00M
Other liab - - - 0.86M 5.07M
Other assets - - 0.00M 13.40M 11.87M
Cash 205.33M 174.96M 127.11M 218.04M 293.48M
Total current liabilities 98.35M 102.21M 77.98M 363.92M 378.25M
Current deferred revenue - - - 290.05M 320.30M
Net debt -163.04M -126.25M -74.86M -157.69M -234.92M
Short term debt 9.55M 12.03M 7.26M 7.32M 5.45M
Short long term debt total 42.29M 48.71M 52.24M 60.35M 58.55M
Other stockholder equity 3062.72M 2764.88M 2144.81M 2018.62M 1608.24M
Property plant equipment - - - 74.52M 69.61M
Total current assets 900.66M 864.44M 1064.14M 1372.32M 897.23M
Long term investments 98.32M 359.37M - 0.00M 425.45M
Net tangible assets - - - 1042.43M 962.29M
Short term investments 662.55M 657.37M 907.40M 1118.17M 571.93M
Net receivables 2.18M 2.17M 2.70M - 1.23M
Inventory - - 0.00M - -
Accounts payable 3.33M 11.14M 9.48M 2.79M 4.78M
Accumulated other comprehensive income 0.68M 2.02M 0.64M -6.89M -2.50M
Common stock total equity - - - - 1.55M
Retained earnings total equity - - - - -645.00M
Non currrent assets other 124.26M 24.74M 16.54M 13.40M 11.87M
Non current assets total 244.20M 509.74M 89.78M 87.92M 506.93M
Capital lease obligations 36.76M 48.71M 52.24M 60.35M 58.55M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 264.78M -88.76M 48.70M -141.39M -13.13M
Change to liabilities - - - -32.19M -11.96M
Total cashflows from investing activities 255.28M -88.76M 249.31M -141.39M -21.63M
Net borrowings -8.17M -32.34M 0.00M - -
Total cash from financing activities 189.22M 484.30M 17.82M 310.67M 19.35M
Change to operating activities - - - 8.16M -8.46M
Net income -512.54M -422.77M -145.22M -325.99M -290.58M
Change in cash 31.90M 47.85M -90.94M -75.43M -213.67M
Begin period cash flow 176.53M 128.68M 218.04M 294.98M 508.64M
End period cash flow 208.43M 176.53M 127.11M 219.54M 294.98M
Total cash from operating activities -412.60M -347.69M -357.99M -244.72M -211.39M
Issuance of capital stock 189.25M 499.25M 0.00M 296.21M 0.00M
Depreciation 14.81M 8.99M 16.73M 10.38M 8.59M
Sale purchase of stock - - - - 19.35M
Other cashflows from financing activities 189.22M 17.39M 17.82M 14.46M 19.35M
Change to netincome - - - 94.92M 91.01M
Capital expenditures 9.50M 15.91M 12.94M 17.83M 8.50M
Cash flows other operating - - - - -31.51M
Cash and cash equivalents changes - - - - -213.67M
Change in working capital 0.15M 16.94M -289.93M -24.03M -20.41M
Stock based compensation 99.63M 102.88M 108.10M 99.85M 85.25M
Other non cash items -14.65M -53.73M -47.67M -4.92M -2.98M
Free cash flow -422.10M -363.61M -370.93M -262.55M -219.89M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DNLI
Denali Therapeutics Inc
0.42
2.33%
18.42 - - 3643.65 3.21 2843.16 86.48
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

650 866 8547

503

Name Title Year Born
Dr. Ryan J. Watts Ph.D. Co-Founder, Pres, CEO & Director 1976
Dr. Alexander O. Schuth M.D. Co-Founder, CFO, COO & Sec. 1973
Dr. Marc Tessier-Lavigne Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1960
Dr. Carole Ho M.D. Chief Medical Officer & Head of Devel. 1973
Mr. Steve Edward Krognes Treasurer & Director 1968
Mr. Tyler M. Nielsen Sr. VP of Corp. Fin. 1978
Dr. Dana Andersen Chief Technical and Manufacturing Officer NA
Mr. Joe Lewcock Chief Scientific Officer NA
Dr. Laura Hansen VP of Investor Relations NA
Mr. Chris Walsh Gen. Counsel NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…